A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients with Stages IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients with Stages IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer (NSCLC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2016 Status changed from active, no longer recruiting to discontinued.
    • 11 Mar 2016 Planned End Date changed to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 11 Mar 2016 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top